目的观察树突细胞与细胞因子诱导杀伤(DC-CIK)细胞疗法联合化疗治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法选取2013年8月—2016年5月四平市中心人民医院收治的晚期NSCLC患者59例,采用随机数字表法分为对照组30例和观察组29例。对照组患者接受长春瑞滨联合顺铂(NP)化疗方案,观察组患者在NP化疗方案基础上接受DC-CIK细胞疗法。比较两组患者治疗前后外周血淋巴细胞表型〔包括T淋巴细胞(CD_3~+)、辅助性T细胞(CD_4~+)、辅助/诱导T淋巴细胞(CD_3~+CD_4~+)、抑制/细胞毒T淋巴细胞(CD_3~+CD+8)、自然杀伤细胞(NK)、自然杀伤性T细胞(NKT)〕及临床疗效、毒副作用发生情况。结果治疗前两组患者外周血CD_3~+、CD_4~+、CD_3~+CD_4~+、CD_3~+CD+8、NK、NKT分数比较,差异无统计学意义(P>0.05);治疗后对照组患者外周血CD_3~+、CD_4~+、CD_3~+CD_4~+、CD_3~+CD+8、NK、NKT分数低于观察组(P<0.05)。治疗后对照组患者外周血CD_3~+、CD_4~+、CD_3~+CD_4~+、CD_3~+CD+8、NK、NKT分数低于治疗前(P<0.05);治疗后观察组患者外周血CD_3~+、CD_4~+、CD_3~+CD_4~+、CD_3~+CD+8、NK分数与治疗前比较,差异无统计学意义(P>0.05),而治疗后观察组患者外周血NKT分数高于治疗前(P<0.05)。观察组患者临床疗效优于对照组(P<0.05)。两组患者毒副作用发生率比较,差异无统计学意义(P>0.05)。结论相对于单纯化疗,DC-CIK细胞疗法联合化疗对NSCLC患者的实体瘤控制效果更佳,能更好地提高患者细胞免疫功能。 Objective To observe the clinical efficacy of dendritic cells combined with cytokine-induced cytotoxicity (DC-CIK) cell therapy in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Fifty-nine patients with advanced NSCLC who were admitted to People’s Hospital of Siping City from August 2013 to May 2016 were divided into control group (n = 30) and observation group (n = 29) by random number table. Patients in the control group received vinorelbine plus cisplatin (NP) chemotherapy and patients in the observation group received DC-CIK cell therapy on the basis of NP chemotherapy. The phenotypes of peripheral blood lymphocytes (including T lymphocytes (CD_3 ~ +), helper T cells (CD_4 ~ +), helper / induced T lymphocytes (CD_3 ~ + CD_4 ~ Cytotoxic T lymphocytes (CD_3 ~ + CD +8), natural killer cells (NK), natural killer T cells (NKT)] and clinical efficacy, side effects. Results There was no significant difference in the scores of CD_3 ~ +, CD_4 ~ +, CD_3 ~ + CD_4 ~ +, CD_3 ~ + CD + 8, NK and NKT in the peripheral blood of the two groups before treatment The scores of CD_3 ~ +, CD_4 ~ +, CD_3 ~ + CD_4 ~ +, CD_3 ~ + CD + 8, NK and NKT in the peripheral blood in the patients were lower than those in the observation group (P <0.05). After treatment, the levels of CD_3 ~ +, CD_4 ~ +, CD_3 ~ + CD_4 ~ +, CD_3 ~ + CD + 8, NK and NKT in peripheral blood of patients in the control group were lower than those before treatment (P < There was no significant difference in NK score between the three groups (P> 0.05), while the NKT scores of the peripheral blood of patients in the observation group after treatment Higher than before treatment (P <0.05). The clinical efficacy of the observation group was better than that of the control group (P <0.05). There was no significant difference in the incidence of side effects between the two groups (P> 0.05). Conclusion Compared with chemotherapy alone, DC-CIK cell therapy combined with chemotherapy has a better control effect on solid tumors in patients with NSCLC, and can better improve cellular immune function.